Access the full text.
Sign up today, get DeepDyve free for 14 days.
M.J. Moore, L. Kaizer, C. Erlichman, R. Bunting, R. Feld, S. Fine, R. Myers, J.J. Thiessen, S. Yuan (1992)
A phase II clinical and pharmacologic study of 5-fluorouracil (5FU) + leucovorin + interferon in advanced colorectal cancerProc. Am. Soc. Clin. Oncol., 11
F.M. Muggia, F.J. Camacho, B.H. Kaplan, M.D. Green, E.S. Greenwald, J.C. Wernz, P.F. Engstrom (1987)
Weekly 5-fluorouracil combined with PALA: Toxic and therapeutic effects in colorectal cancerCancer Treat. Rep., 71
C. Aschele, A. Sobrero, M.A. Faderan, J.R. Bertino (1992)
Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedulesCancer Res., 52
Y.M. Rustum, S. Madajewicz, J. Cambell, H.W. Bruckner, Y. Rustum (1984)
Clinical, biochemical pharmacology of 5-formyltetrahydrofolate in combination with 5-fluorouracil in patients with advanced colorectal carcinoma: Correlation with clinical responseThe current status of 5-fluorouracil-leucovorin combination
C.H. Schöber, C.H. Köhne-Wömpner, H.J. Schmoll, M. Stahl, H.J. Wilke, H. Poliwoda (1992)
A 3-day schedule of 5-fluorouracil and folinic acid in metastatic progressive colorectal cancer and its impact in terms of palliationSemin. Oncol., 2
C.A. Presant, B. Ardalan, P. Multhauf (1983)
Continuous five-day infusion of PALA and 5-FU: A pilot phase II trialMed. Pediatr. Oncol., 11
G.R. Weiss, T.J. Ervin, M.W. Meshad, D.W. Kufe (1982)
Phase II trial of combination therapy with continuous infusion PALA and bolus injection 5-FUCancer Treat. Rep., 66
B. Ardalan, G. Singh, H. Silberman (1988)
A randomized phase I and II study of short term infusion of high-dose fluorouracil with or without N-(phosphonoacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancersJ. Clin. Oncol., 6
G.A. Van Hazel, M. Buck, N.J. Byrne (1992)
Phase II study of the combination of 5-fluorouracil (5FU), folinic acid (FA) and alpha interferon (IFN) in metastatic colorectal adenocarcinoma cancer (CC)Proc. Am. Soc. Clin. Oncol., 11
R.M. Evans, J.D. Laskin, M.T. Hakala (1981)
Effect of excess folates and deoxylnosine on the activity and site of action of 5-fluorouracilCancer Res., 41
D. Hunting, J.F. Henderson (1982)
Relation between ribo- and deoxyribonucleotide concentrations and biological parameters in cultured Chinese hamster ovary cellsBiochem. Pharmacol., 31
J. Cunningham, R.M. Bukowski, G.T. Budd, J.K. Weick, J. Purvis (1984)
5-fluorouracil and folinic acid: A phase I–II trial in gastrointestinal malignancyInvest. New Drugs., 2
J.J. Lokich, J.D. Ahlgren, J.J. Gullo, J.A. Philips, J.G. Fryer (1989)
A prospective randomized comparison of continuous infusion with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program StudyJ. Clin. Oncol., 7
R. Cellerino, S. Antognoli, L. Giustini, L. Acito, M. Marcellino (1994)
A randomized study of fluorouracil (5-FU) with or without alpha-interferon (IFN) in advanced colorectal cancerProc. Am. Soc. Clin. Oncol., 13
P. Piedbois, M. Buyse (1993)
What can we learn from a meta-analysis of trials testing the modulation of 5-FU by leucovorin?Ann. Oncol., 4
P.G. Johnston, J.C. Drake, J. Trepel, C.J. Allegra (1992)
Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and resistance human cancer cell linesCancer Res., 52
H.M. Pinedo, G.J. Peters (1988)
Fluorouracil: biochemistry and pharmacologyJ. Clin. Oncol., 6
K. Pittman, T. Perren, N. Ward, J. Primrose, M. Slevin, N. Patel, P. Selby (1993)
Pharmacokinetics of 5-fluorouracil in colorectal cancer patients receiving interferonsAnn. Oncol., 4
D.S. Gewert, G. Moore, M.J. Clemens (1983)
Inhibition of cell division by interferons: The relationship between changes in utilization of thymidine for DNA synthesis and control of proliferation in Daudi cellsBiochem. J., 214
A. Sobrero, M.T. Nobile, A. Guglielmi, A. Mori, C. Aschele, E. Bolli, L. Tixi, L. Gallo, G.C. Parodi, P. Bruzzi, F. Brema, R. Rosso (1992)
Phase II study of 5-fluorouracil plus leucovorin and interferon alpha 2b in advanced colorectal cancerEur. J. Cancer, 4/5
F. DiCostanzo, R. Bartolucci, D. Padalino, M. Brugia, F. Buzzi (1988)
High-dose folinic acid and 5-fluorouracil in advanced colorectal cancerCancer Invest., 6
J.L. Grem, N. McAtee, R.F. Murphy, F.M. Balis, S.M. Steinberg, J.M. Hamilton, J.M. Sorensen, O. Sartor, B.S. Kramer, L.J. Goldstein, L.M. Gay, K.M. Caubo, B. Goldspiel, C.J. Allegra (1991)
A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinomaJ. Clin. Oncol., 10
B. Steinke, E. Gunther, W.D. Hirscmann (1991)
Fluorouracil versus folinic acid/fluorouracil in advanced colorectal cancer — preliminary results of a randomized trialSemin. Oncol., 18
R. Pazdur, B. Bready, D.F. Moore (1991)
Clinical trials of fluorouracil with alpha-interferon in advanced colorectal carcinomaSemin. Oncol., 18
A.F. Sobrero, C. Aschele, A.P. Guglielmi (1993)
Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cellsJ. Natl. Cancer Inst., 85
M.W. Meshad, T.J. Ervin, D. Kufe, R.K. Johnson, R.H. Blum, E. Frei (1981)
Phase I trial of combination therapy with PALA and 5-FUCancer Treat. Rep., 65
C.G. Moertel, T.R. Fleming, J.S. MacDonald (1990)
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinomaN. Engl. J. Med., 322
E. Jäger, O. Klein, H. Bernhard, B. Wächter, M. Heike, W. Dippoid, K.-H. Meyer zum Buschenfelde, A. Knuth (1994)
Weekly high-dose folinic acid (FA)/5-fluorouracil (FU) vs low dose FA/FU in advanced colorectal cancer. Results of a randomized multicenter trialProc. Am. Soc. Clin. Oncol., 13
P.J. Byrne, J. Treat, M. McFadden, H.W. Bruckner, Y.M. Rustum (1984)
Therapeutic efficacy of the combination of 5-fluorouracil and high-dose leucovorin in patients with advanced colorectal carcinoma: Single daily intravenous dose for five daysThe Current Status of 5-fluorouracil-Leucovorin Calcium Combination
P.J. O’Dwyer, A.R. Paul, J. Walczak (1990)
Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancerJ. Clin. Oncol., 8
P. Lavin, A. Mittelman, H. Douglas, P. Engström, D. Klassen (1980)
Survival and responses to chemotherapy for advanced colorectal carcinomaCancer, 46
C. Erlichman, R.C. Donehower, J.L. Speyer (1982)
A phase I–II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injectionJ. Natl. Cancer Inst., 68
L. Elias, J.M. Sandoval (1989)
Interferon effects upon fluouracil metabolism by HL-60 cellsBiochem. Biophys. Res. Commun., 163
K.D. Collins, G.R. Stark (1971)
Aspartate transcarbamylase, interaction with the transition state analogue N-(phosphon-acetyl) L-aspartateJ. Biol. Chem., 246
A.F. Sobrero, C. Aschele, A.P. Guglielmi, A.M. Moria, S. Mammoliti, L. Tixi, E. Bolli, R. Rosso, J.R. Bertino (1994)
High activity and low toxicity of alternating bolus and continuous infusion 5-fluorouracil with schedule oriented biochemical modulationProc. Am. Soc. Clin. Oncol., 13
R.D.E. Sullivan, W.Z. Miller, R.A. Zurek, Y. Ojima (1969)
Reevaluation of methotrexate as an anticancer drugSurg. Gynecol. Obstet., 125
G. Lundell, H. Blomgren, B. Cedermark, C. Silfverswärd, T. Theve, U. Öhman (1984)
High-dose rDNA human alpha2 interferon therapy in patients with advanced colorectal adenocarcinoma: A phase II studyRadiother. Oncol., 1
H.W. Bruckner, L.L. Glass, M.R. Chesser (1990)
Dose-dependent leucovorin efficacy with an intermittent high dose 5-fluorouracil scheduleCancer Invest., 8
E. Cadman, R. Heimer, L. Davis (1979)
Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergismScience, 205
J.Y. Douillard, J. Leborgne, J.Y. Danielou, P.A. Lehur, L. Potiron, J.C. Le Neel, J.L. Bolze, P. Jutel (1991)
Phase II trial of 5-fluorouracil (5-FU) and recombinant alpha-interferon (R alpha-IFN) (Intron A) in metastatic, previously untreated colorectal cancer (CRC)Proc. Am. Soc. Clin. Oncol., 10
(1990)
Preoperative short-term radiation therapy in operable rectal carcinoma. A prospective randomized trialCancer, 66
G.A. Higgins (1983)
Current status of adjuvant therapy in the treatment of large bowel cancerSurg. Clin. North. Am., 63
W.J. John, R.J. Neefe, J.S. McDonald, J. Cantrell, M. Smith (1993)
5-fluorouracil and interferon-alpha-2a in advanced colorectal cancer. Results of two treatment schedulesCancer, 72
A. Fornasiero, O. Daniele, C. Ghiotto, S.M. Aversa, P. Morandi, M.V. Fiorentino (1990)
Alpha-2 interferon and 5-fluorouracil in advanced colorectal cancerTumori, 76
G.J. Jansson-Frykholm, B. Glimelius, L. Påhlman (1993)
Preoperative and postoperative irradiation in adenocarcinoma randomized trial and an evaluation of late secondary effectsDis. Colon Rectum, 36
T.R. Buroker, C.G. Moertel, T.R. Fleming (1985)
A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinomaJ. Clin. Oncol., 3
S. Wadler, E.L. Schwartz (1990)
Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A reviewCancer Res., 50
T. Löffler, F.W. Korsten, F. Burghardt, H.E. Reis, E. Aulbert, W. Lindemann, M. Schröder, T.U. Hausamen, G. Strohmeyer, H.E. Planker (1992)
Randomized comparison of 5-FU vs 5-FU median dose leucovorin in metastatic colorectal cancerDtsch. Med. Wochenschr., 117
C. Allegra, M.E. Lippman, B.A. Chabner (1988)
The salvage treatment of patients with metastatic breast cancer with 5-fluorouracil and leucovorinThe expanding role of folates and fluoropyrimidines in cancer chemotherapy, an International Symposium
E.S. Casper, K. Vale, L.J. Williams, D.S. Martin, C.W. Young (1983)
Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acidCancer Res., 43
M.T. Seymour, N. Patel, A. Johnston, S.P. Joel, M.L. Slevin (1994)
Lack of effect of interferon alpha2a upon fluorouracil pharmacokineticsBr. J. Cancer, 70
J.L. Clark, S.H. Berger, A. Mittelman (1987)
Thymidylate synthase overproduction gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapyCancer Treat. Rep., 71
A.Y. Bedikian, J.R. Stroehlein, D.A. Karlin, R.W. Bennetts, G.P. Bodey, M. Valdivieso (1981)
Chemotherapy for colorectal cancer with a combination of PALA and 5-FUCancer Treat. Rep., 65
C. Punt, M. Burghouts, J. Croles, P. van Liessum, P. de Mulder, Y. Kamm (1993)
Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer: A multicentre phase II studyCancer, 72
M. Huberman, E. McClay, M. Atkins, H. Goldsweig, D. Bonanno, M. Layton, J. Tessitore (1991)
Phase II trial of 5-fluorouracil (5-FU) and recombinant interferon-alpha-2a (IFN) in advanced colorectal cancerProc. Am. Soc. Clin. Oncol., 10
C. Erlichman, S. Fine, A. Wong, T. Elhakim (1988)
A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinomaJ. Clin. Oncol., 6
C.E. Moore, J. Friedman, M. Valdivieso (1982)
Aspartate carbamoyltransferase activity, drug concentrations and pyrimidine nucleotides in tissue from patients treated with N-(phosphonoacetyl)-L-aspartateBiochem. Pharmacol., 31
J.L. Grem, E. Jordan, M.E. Robson, R.A. Binder, J.M. Hamilton, S.M. Steinberg, S.G. Arbuck, R.A. Beveridge, A.N. Kales, J.A. Miller, R.B. Weiss, N. McAtee, A. Chen, B. Goldspiel, E. Sover, C.J. Allegra (1993)
Phase II study of fluorouracil, leucovorin and interferon alfa-2a in metastatic colorectal carcinomaJ. Clin. Oncol., 11
A. Martoni, A. Cricca, M. Guaraldi, M. Covizzi, A. Farris, F. Pannuti (1992)
Weekly regimen of 5-FUvs 5-FU + intermediate dose folinic acid in the treatment of advanced colorectal cancerAnticancer Res., 12
P. Rougier, J.P. Droz, M. Ducreux, J. Kac, M. Spielmann, B. Crespon, G. Ley, P. Zimmerman, C. Theodore, A. Chavy (1983)
Treatment of advanced colonic and rectal adenocarcinoma: Combination of 5-FU and high-dose folinic acidBull. Cancer (Paris), 70
N. Petrelli, L. Herrera, Y. Rustum, P. Burke, P. Creaven, J. Stulc, L.J. Emrich, A. Mittelman (1987)
A prospective randomized trial of 5-fluorouracil vs 5-fluorouracil and high-dose leucovorin vs 5-fluorouracil and high-dose leucovorin vs 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinomaJ. Clin. Oncol., 5
S.M. Swain, M.E. Lippman, E.F. Egan (1989)
Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancerJ. Clin. Oncol., 7
R. Herman, A.M. Knuth, U. Kleeberg (1986)
Randomized multicenter trial of sequential methotrexate (MTX) and 5-fluorouracil (FU) vs FU alone in metastatic colorectal carcinomas (CRC)Proc. Am. Soc. Clin. Oncol., 5
C. Wasternack (1980)
Degradation of pyrimidines and pyrimidine analogs — pathways and mutual influencesPharmacol. Ther., 8
(1992)
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rateJ. Clin. Oncol., 10
D. Rubio, J. Jimeno, C. Camps, E. Aranda, B. Massuti, E. Blanco, A. Anton, J. Lizon, J.L. Gonzalez-Larriba (1992)
Treatment of advanced colorectal cancer with recombinant interferon alpha and fluorouracil: Activity in liver metastasisClin. Invest., 10
H.L. Davis (1982)
Chemotherapy of large bowel cancerCancer, 50
S. Madajewicz, N. Petrelli, Y.M. Rustum, J. Campbell, L. Herrera, A. Mittelman, A. Perry, P.J. Creaven (1984)
Phase I–II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancerCancer Res., 44
M.A. Poon, M.J. O’Connel, C.G. Moertel, H.S. Wieand, S.A. Cullinan, L.K. Everson, J.E. Krook, J.A. Mailliard, J.A. Laurie, L.K. Tschetter, M. Wiesenfeld (1989)
Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinomaJ. Clin. Oncol., 7
M.A. Poon, M.J. O’Connell, H.S. Wieand, C.G. Krook, J.B. Gerstner, L.K. Tschetter, R. Levitt, C.G. Kardinal, J.A. Mailliard (1991)
Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancerJ. Clin. Oncol., 9
E.D. Kreuser, R.U. Hilgenfeld, M. Matthias, B. Hoksch, C. Boewer, B. Oldenkott, H. Lenk, N. Wiener, A. Schalhorn, E. Thiel, J. Boese-Landgraf (1992)
Final update on a phase II trial of interferon alfa-2b with folinic acid and a 4-hour infusion of 5-fluorouracil in advanced colorectal carcinomaSemin. Oncol., 2
F.H. Valone, M.A. Friedman, P.S. Wittlinger, T. Drakes, P.D. Eisenberg, M. Malec, J.F. Hannigan, B.W. Brown (1989)
Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil or sequential methotrexate, fluorouracil and leucovorin. A randomized trial of the Northern California Oncology GroupJ. Clin. Oncol., 7
P.I. Clark, M.L. Slevin, R.H. Reznek, N. Niederle, E. Kurschel, G. Lundell, B. Cedermark, A. Fallenius, H. Blomgren, U. Öhman, C. Silfverswärd, T. Theve, P.F.M. Wrigley (1987)
Two randomized phase II trials of intermittent intravenous vs subcutaneous alpha2 interferon alone (trial 1) and in combination with 5-fluorouracil (trial 2) in advanced colorectal cancerInt. J. Colorectal. Dis., 2
N. Kemeny, A. Younes, K. Seiter, D. Kelsen, P. Sammarco, L. Adams, S. Derby, P. Murray, C. Houston (1990)
Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinomaCancer, 66
B. Lembersky, H. Koff, L. Miketic, M. Posner, S. Jacobs, B. Carr (1992)
Phase II trial of 5-fluorouracil (FU) leucovorin (LV) and interferon alfa-2b (IFN) in the treatment of metastatic colorectal cancer (CRC)Proc. Am. Soc. Clin. Oncol., 11
J.L. Abbruzzese, B. Levin (1989)
Treatment of advanced colorectal cancerHematology/Oncology Clinics of North America, 3
J.L. Grem, E. Chu, D. Boarman, F.M. Balis, R.F. Murphy, N. McAtee, C.J. Allegra (1992)
Biochemical modulation of fluorouracil with leucovorin and interferon: preclinical and clinical investigationsSemin. Oncol., 19
S. Wadler, P.H. Wiernick (1990)
Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinomaSemin. Oncol., 17
N. Kemeny, P. Costa, J.A. Conti, K. Seiter, D. Niedzwiecki, J. Botet, D. Martin, J. Wiseberg, W. McCulloch (1992)
Phase II trial of PALA and 5-FU in metastatic colorectal carcinomaJ. Clin. Oncol., 5
M. York, F.A. Greco, R.A. Figlin, L. Einhorn, T. Man, L. Cockey, D. Mott, S.E. Light (1993)
A randomized phase III trial comparing 5-FU with or without interferon ALFA 2a for advanced colorectal cancerProc. Am. Soc. Clin. Oncol., 12
C. Lindley, S. Bernard, M. Gavigan (1990)
Interferon-alpha increases 5-fluorouracil (5-FU) plasma levels 64-fold within one hour: Results of a phase I studyJ. Interferon. Res., 10
M.T. Nobile, M.G. Vidili, A. Sobrero, R. Rosso, M.R. Sertoli, A. Rubagotti, A. Guglielmi, M. Venturini, L. Canobbio, T. Fassio, L. Gallo (1992)
5-fluorouracil alone or combined with high dose folinic acid in advanced colorectal cancer patients: A randomized trialEur. J. Cancer, 28A
H.W. Bruckner, J. Roboz, E. Ambinder, H.W. Bruckner, Y.M. Rustum (1984)
An efficient leucovorin-5-fluorouracil sequence: Dosage escalation and pharmacological monitoringThe current status of 5-fluorouracilleucovorin calcium combination
P. Seifert, D.O. Baker, M.D. Reed, H. Laurence, L. Melvin, V.K. Vaitkevicius (1975)
Comparison of continuously infused 5-fluorouracil with bolus injections in treatment of patients with colorectal adenocarcinomaCancer, 36
I. Brunetti, A. Falcone, M. Bertuccelli, P.G. Giannessi, P.F. Conte, C. Cianci, S. Ricci (1994)
Double 5-fluorouracil (5-FU) modulation with folinic acid (FA) and recombinant alfa 2-B interferon (IFN) in patients (PTS) with metastatic colorectal carcinoma (MCRC)Am. J. Clin. Oncol., 3
H.J. Schmoll, C.H.Y. Kohne-Wömpner, W. Hiddemann, H. Rauschecker, C. Preiss, J. Balleisen, H.P. Lohrman, J.T.H. Fischer, A. Harstrick (1992)
Bolus 5-fluorouracil (FU), folinic acid (FA) and alpha-2b interferon (IFN) in advanced colorectal cancer (CRC): A multicentre phase II trialProc. Am. Soc. Clin. Oncol., 11
M.J. O’Connell, G. Powis, J. Rubin, C.G. Moertel (1982)
Pilot study of PALA and 5-FU in patients with advanced cancerCancer Treat. Rep., 66
(1989)
Superiority of sequential methotrexate, fluorouracil and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trialJ. Clin. Oncol., 7
(1993)
Biochemical modulation of 5-fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancerAnn. Oncol., 4
J.A. Houghton, J.J. Maroda, J.O. Phillips, P.J. Houghton (1981)
Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinoma in miceCancer Res., 41
L.D. Nord, R.L. Stolfi, D.S. Martin (1993)
Biochemical modulation of 5-fluorouracil with leucovorin or delayed uridine rescueBiochem. Pharmacol., 44
C.G. Leichman, F.M. Fleming, B. Muggia, J. Ardalan, C. Doroshow, C. Tangen, J. MacDonald (1993)
Fluorouracil (5-FU) schedules and modulation in advanced colorectal cancer (CRC): A Southwest Oncology Group (SWOG) screening trialProc. Am. Soc. Clin. Oncol., 12
J. Barankiewicz, C. Kaplinsky, A. Cohen (1986)
Modification of ribonucleotide and deoxyribonucleotide metabolism in interferon treated B-lymphoblastoid cellsJ. Interferon Res., 6
C.L. Van der Wilt, H.M. Pinedo, K. Smid (1992)
Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by addition of leucovorin in murine colon tumorsCancer Res., 52
M. Tempero, A. Berg, M. Block, M. Hutchins, D. Moravec, R. Langdon (1993)
A phase II trial of protracted therapy with 5-fluorouracil and leucovorin in metastatic colorectal cancerProc. Am. Soc. Clin. Oncol., 12
J.C. Marsh, J.R. Bertino, L.S. Rome (1989)
Sequential methotrexate, 5-fluorouracil and leucovorin in metastatic colorectal cancer: A controlled comparison of two intervals between drug administrationProc. Am. Soc. Clin. Oncol., 8
C.P. Spears, B.G. Gustavsson, M. Berne, R. Frösing, L. Bernstein, A. Hayes (1988)
Mechanism of innate resistance to thymidylate inhibition after 5-fluorouracilCancer Res., 48
S. Spiegelman, R. Nayak, R. Sawyer, R. Stolfi, D. Martin (1980)
Potentiation of the anti-tumor activity of 5-FU by thymidine and its correlation with the formation of (5-FU) RNACancer, 45
L.K. Yee, C.J. Allegra, S.M. Steinberg, J.L. Grem (1992)
Decreased catabolism of 5-fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin, and interferon alfa-2aJ. Natl. Cancer Inst., 84
T. Horikoshi, K.D. Danenberg, T.H.W. Stadlbauer, M. Volkenandt, L.C.C. Shea, K. Aigner, B. Gustavsson, L. Leichman, R. Frösing, M. Ray, N.W. Gibson, C.P. Spears, P.V. Danenberg (1992)
Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reactionCancer Res., 52
R.G. Moran, K.L. Scanion (1991)
Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acidCancer Res., 51
S. Wadler, E.L. Schwartz, M. Goldman, A. Lyver, M. Rader, M. Zimmerman, L. Itri, V. Weinberg, P.H. Wiernik (1989)
Fluorouracil and recombinant alpha-2a-interferon: An active regimen against advanced colorectal carcinomaJ. Clin. Oncol., 7
W. Kocha (1993)
(Corfu-A Collaborative Group): 5-FU plus interferon alpha 2a vs 5-FU + leucovorin in metastatic CRC — results of a multicentre multinational phase III studyProc. Am. Soc. Clin. Oncol., 12
M.J. O’Connel (1989)
A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancerCancer, 63
L. Danhauser, T.L. Gilchrist, J.H. Freimann (1991)
Effect of recombinant interferon-alpha2b on the plasma pharmacokinetics of fluorouracil in patients with advanced cancerProc. Am. Assoc. Cancer Res., 32
J.R. Neefe, W. John (1991)
Mechanism of interaction of interferon and 5-fluorouracil in solid tumorsSem. Oncol., 18
H. Wilke, H.J. Schmoll, C. Schober (1980)
Folinic acid (FA) plus 5-fluorouracil (5-FU) in progressive advanced colorectal cancerBiomed. Pharmacother., 42
H.J. Weh, D. Platz, D. Braumann, P. Buggisch, N. Eckardt, W.H. Schmiegel, S. Drescher, U.R. Kleeberg, U. Mullerleile, W. Crone-Munzebrock (1992)
Phase II trial of 5-fluorouracil and recombinant interferon alfa-2b in metastatic colorectal carcinomaEur. J. Cancer, 28A
T. Kensler, C. Erlichman, H.N. Jayararam, A.K. Tyagi, B. Ardalan, D.A. Cooney (1980)
Peripheral leukocytes as indicators of the enzymic effect of N-(Phosphonoacetyl)-L-aspartic acid on human L-aspartate transcarbamoylase (ACTase) activityCancer Treat. Rep., 64
S.H. Berger, K.W. Barbour, F.G. Berger (1988)
A naturally occuring variation in thymidylate synthase structure is associated with a reduced response to 5-fluoro-2′-deoxyuridine in a human colon tumor cell lineMol. Pharmacol., 34
L. Elias, H.A. Crissman (1988)
Interferon effects upon the adenocarcinoma 38 and H1-60 cell lines: Antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolitesCancer, 48
E.L. Schwartz, N. Babtiste, C.J. O’Connor, S. Wadler, B.A. Otter (1994)
Potentiation of the antitumor activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary effects on thymidine phosphorylaseCancer Res., 54
R. Labianca, G. Giaccon, G. Pancera, G. Ambrosini, G. Amichetti, S. Barni, S. Cascinu, G. Martignoni, G. Pavaaanato, R. Scapaticci, A. Zaniboni, G. Luporini (1992)
Low dose alfa2b interferon (IFN) + folinic acid (FA) + 5-fluorouracil (5FU) in advanced colorectal cancer (ACC): A phase II study of giscad (Italian group for the study of gastrointestinal cancer)Proc. Am. Soc. Clin. Oncol., 11
J.D. Hines, D.J. Adelstein, J.L. Spiess, P. Giroski, S. Gear Carter (1989)
Efficacy of high-dose oral leucovorin and 5-fluorouracil in advanced colorectal carcinoma. Plasma and tissue pharmacokineticsCancer, 63
D. Brohée (1991)
5-fluorouracil (5FU) with or without folinic acid (LV) in human colorectal cancer? Multivariate meta-analysis of the literatureMed. Oncol. Tumor. Pharmacother., 8
J. Schuller, M. Czeija, M. Micksche, G. Schernthaner, U. Fogl, W. Jäger (1992)
Influence of interferon-alpha2b (IFN) ± leucovorin (LV) on pharmacokinetics (PK) of 5-fluorouracilSemin. Oncol., 2
R. Hansen, P. Ritch, J. Libnock, T. Anderson (1991)
Continuous 5-fluorouracil infusion and alpha interferon in advanced cancers: A report of initial treatment resultsAm. J. Med. Sci., 301
J.H. Doroshow, P. Multhauf, L. Leong, K. Margolin, T. Litchfield, S. Akman, B. Carr, M. Bertrand, D. Goldberg, D. Blayney, O. Odujinrin, R. DeLap, J. Shuster, E. Newman (1990)
Prospective randomized comparison of fluorouracil vs fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapyJ. Clin. Oncol., 8
A.C. Sartorelli, W.A. Creasey, J.F. Holland, E. Frei (1982)
Combination chemotherapyCancer Medicine
P. Ragnhammar, H. Blomgren, D. Edler, G. Lundell, I. Magnusson, T. Sonnenfeld (1995)
Different dose regimens of 5-fluorouracil and IFN-alpha in patients with metastatic colorectal carcinomaEur. J. Cancer, 31A
N. Petrelli, H.O.J. Douglass, L. Herrera, D. Russell, D.M. Stablein, H.W. Bruckner, R.J. Mayer, R. Schinella, M.D. Green, F.M. Muggia, A. Megibow, E.S. Greenwald, R.M. Bukowski, J. Harris, B. Levin, E. Gaynor, A. Loutfi, M.H. Kalser, J.S. Barking, P. Benedetto, P.V. Woolley, R. Nauta, D.W. Weaver, L.P. Leichman (1989)
The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. Gastrointestinal Tumor Study GroupJ. Clin. Oncol., 7
P.G. Johnston, E.R. Fisher, H.E. Rockette, B. Fisher, N. Wolmark, C.J. Allegra, J.C. Drake, B.A. Chabner (1994)
The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancerJ. Clin. Oncol., 12
A. De Gramont, M. Krulik, J. Cady, B. Lagadec, J.-E. Maisani, J.-P. Loiseau, J.-D. Grange, G. Gonzalez-Canali, B. Demuynck, C. Louvet, J. Seroka, C. Dray, J. Debray (1988)
High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancerEur. J. Cancer Clin. Oncol., 24
F. Di Constanzo, R. Bartolucci, R. Calabresi, M. Sofra, M. Marzola, V. Belsanti, C. Boni, M. Bacchi (1992)
Fluorouracil alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: A randomized trial of the Italian Oncology Group for Clinical ResearchAnn. Oncol., 3
L.L. Danhauser, J.H. Freimann, T.L. Gilchrist, J.U. Gutterman, C.Y. Hunter, A.C. Yeomans, A.B. Markowitz (1993)
Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alpha-2b in patients with advanced cancerJ. Clin. Oncol., 11
A. Fedeli, S.L. Fedeli, G. Catalano (1991)
Double biochemical modulation of 5-fluorouracil by leucovorin and cyclic low dose interferon alpha 2b in advanced colorectal cancer patientsAnn. Oncol., 3
B. Weinerman, A. Shah, A. Fields, I. Kerr, C. Cripps, F. Shepherd, K. Wilson, R. McCormick, W. Temple, J. Maroun, W. Bogues, J. Pater (1992)
A randomized trial of continuous systemic infusion (SI)vs bolus therapy (B) with 5-fluorouracil (5-FU) in metastatic measurable colorectal cancer (MCC)Am. J. Clin. Oncol. Dec., 15
S.H. Berger, C.H. Jenh, L.F. Johnson (1985)
Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cellsMol. Pharmacol., 28
R. Labianca, G. Pancera, G. Beretta, E. Aitini, S. Barni, G.D. Beretta, B. Cesana, G. Comella, L. Cozzaglio, M. Cristoni (1991)
A randomized study of intravenous fluorouracil +/- folinic acid in advanced metastatic colorectal carcinomaAnn. Oncol. Oct., 2
D.G. Priest, S.E. Ledford, M.T. Doig (1980)
Increased thymidylate synthetase in 5-fluorodeoxyuridine resistant cultured hepatoma cellsBiochem. Pharmacol., 29
MEDICAL ONCOLOGY (1995) 12, 187-201 How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer PETER RAGNHAMMAR* and HENRIC BLOMGREN Department of Oncology (Radiumhemmet), Karotinska Hospital, S-171 76 Stockholm, Sweden Keywords: 5-fluorouracil; colorectal carcinoma mented, or modulated; by other agents which INTRODUCTION exhibit little if any antitumor activity by them- selves. This rapidly progressive research field is Colorectal adenocarcinoma is one of the most important since it may yield meaningful che- common tumor types in the industrialized western motherapy schedules for patients with advanced countries. At the time of diagnosis, approximately colorectal cancer. More importantly, such sche- 20% of the patients display clinically detectable dules may be used also in adjuvant settings to spread of the disease to distant sites and 40% to prevent relapses following surgery in high risk locoregional lymph nodes [1]. More than half of cases for primary disease. In fact, there are already the patients who undergo surgical procedures some reports showing that 5-FU based modulated with the intent to cure eventually relapse and die chemotherapy may palliate and prolong life of from their disease [21. Radiation therapy may patients with advanced colorectal cancer I9,10], significantly diminish the local recurrence rate, decrease
Medical Oncology – Springer Journals
Published: Sep 1, 1995
Keywords: 5-fluorouracil; colorectal carcinoma
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.